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Palytoxin (PTX) caused K’ release from rabbit erythrocytes at a concentration as low as 10~” M. The K+ 
release due to PTX at a concentration below 10e9 M was dependent on Ca2+ in medium. The effect of Caz+ 
was substituted fully by Sr2+ and partially by Ba *+ W-7 (2 x 1O-4 M), a known inhibitor of calmodulin. . 
markedly inhibited the rate of K+ release due to PTX. W-5 (2 x 10m4 M), an analog of W-7 with lower affn- 
ity to calmodulin than W-7, showed weaker inhibition. Other calmodulin antagonists, such as prenylamine, 
chlorpromazine and compound 48/80, also inhibited the PTX-induced K+ release. These results suggest that 
the K+ release induced by PTX involves the process(es) mediated by intracellular Ca2+ and calmodulin. 
Palytoxin Calmodulin inhibitor 
1. INTRODUCTION 
Palytoxin (PTX; Crz9H~3N3054; M, 2677), ex- 
tracted from marine coelenterates of the genus 
Palythoa, is the most poisonous animal toxin 
known to date [l]. The stereochemistry of PTX 
has recently been determined [2,3]. PTX in low 
concentrations (lo- “-lo-* M) causes depolariza- 
tion and/or contraction in various types of nerve 
and muscle tissues [4]. PTX also induces the 
release of K+ from erythrocytes [5] and smooth 
muscle cells [6]. Recently, it has been shown that 
the K+ loss induced by PTX in erythrocytes is 
enhanced by external Ca2+ [7]. Here, we have in- 
vestigated the effects of several calmodulin in- 
hibitors on the PTX-induced K+ release from rab- 
bit erythrocytes to determine if calmodulin plays a 
role in this action of PTX. 
2. MATERIALS AND METHODS 
Erythrocytes obtained from rabbit heparinized 
(30 III/ml) blood were washed 3 times in 5 
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K+ release Ervthrocyte 
volumes of physiological salt solution (PSS) 
(NaCl, 136.9 mM; CaC12, 1.0 mM; MgC12, 
1.0 mM; glucose, 5.5 mM; Hepes, 10 mM, pH 
7.3) by centrifugation for 5 min at 3000 rpm. The 
buffy coat was removed by aspiration. Packed 
cells were resuspended in PSS (approximately 
100000 cells/ml) and stored at 4°C. No 
measurable K+ loss was observed during the cold 
storage up to 5 h. Determination of K+ was carried 
out using either K+-selective electrode (Philips, 
IS 561 K) or flame photometer (Hitachi, Type 
208). The latter method was employed in the ex- 
periments with prenylamine, chlorpromazine and 
trifluoperazine, since these compounds change the 
sensitivity of K+-selective electrode. In the ex- 
periments with the K+-selective lectrode, the loss 
of K+ was measured continuously at 37°C. In the 
case of flame photometry, erythrocytes were in- 
cubated with PTX for 27 min at 37°C and the 
reaction was stopped by a 3 min centrifugation at 
2200 rpm at 25°C. The amount of maximum 
releasable K+ was determined by adding saponin 
(lOpg/ml) to the solution at the end of each 
experiment. 
PTX isolated from Palythoa tuberculosa was 
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kindly donated by Dr Y. Hirata (Meija University, 
Nagoya). The toxin was diluted from a 10T4 M 
aqueous stock solution before use with a solution 
containing 0.5% bovine serum albumin and 2 mM 
Hepes (pH 7.0) [7]. Chlorpromazine hydrochlor- 
ide, trifluoperazine dihydrochloride, compound 
48180 (all from Sigma) and verapamil hydrochlor- 
ide (Eisai) were dissolved in distilled water. Prenyl- 
amine lactate (Hoechst, Japan) and R-24571 (cal- 
midazolium) (Boehringer, Mannheim) were dis- 
solved in dimethylsulfoxide. ~-(6-Aminohexyl)-5- 
chloro-I-naphthalenesulfonamide (W-7) and N- 
(6-aminohexyl)-1-naphthalenesulfonamide (W-5) 
(both from Rikaken) were dissolved in PSS. 
Various Ca’+ concentrations were prepared by ad- 
ding appropriate amounts of EGTA to PSS using 
an apparent binding constant of EGTA for Ca2+ 
of 1.61 x lo5 M-r (pH 7.3) [8]. 
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Fig.2. Effect of W-7 and W-S on the time course of K+ 
release induced by PTX. K+ release was continuously 
measured with a K+-selective lectrode. Either W-7 or 
W-5 was added 10 min before the application of PTX 
(10m9 M). (0) Control; (m) W-7 (2 x 10h4 M); (0) W-5 
(2 x 10m4 M). Abscissa, time (min). Ordinate, amount 
3. RESULTS AND DISCUSSION of K+ released by PTX (oio). 
PTX ( 10-10-10-9 M) caused rapid release of K” 
from rabbit erythrocytes in the presence of 1 mM 
Ca*+. When Ca*+ was omitted from PSS 
(nominally free Ca*+), no measurable K+ release 
was observed by PTX (10-‘“-10-9 M), Ex- 
tracellular Ca2+ over IO-’ M augmented the action 
of PTX (10-‘“-10-9 M) (fig.1). PTX at lo-’ M in- 
duced marked K+ release even in the absence of ex- 
tracellular Ca”+ or at below lo-’ M Ca2+ (fig.1). 
Several species of divalent cations were tested for 
their ability to substitute the role of Ca*+ on K+ 
release due to PTX (10v9 M). The effects of Ca*’ 
were substituted fully by Sr*+ (1 mM) and partially 
by Ba*+ (1 mM) (30%). Mn*+ (1 mM) and CO*+ 
(1 mM) were ineffective (not shown). 
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Fig. 1. Ca*+ dependency of the K’ release due to PTX. 
The amount of K+ released during a 20 min PTX- 
incubation period was measured with a K+-selective 
electrode. Ca’+ concentration in medium was changed 
10 min before the application PTX by adding 
appropriate amounts of EGTA. Concentration of PTX: 
(0) lo”* M; (0) 10m9 M; (m) 10-‘” M. Abscissa, 
logarithm of free Ca’+ concentration (M). Ordinate, 
amount of K+ released by PTX (%‘o). 
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In the next experiment, the effects of calmodulin 
inhibitors on the K+ release due to PTX were in- 
vestigated. Fig.2 shows the effects of W-7 (2 x 
10e4 M) and W-5 (2 x 10e4 M) on the K+ release 
due to PTX (low9 M). W-7 strongly inhibited the 
rate of the I<+ release induced by PTX. W-5, an 
analog of W-7 which has no chloride in the struc- 
ture and possesses a lower affinity to calmodulin 
than W-7 191, showed less inhibition. As shown in 
fig.3, chlorpromazine (10e4 M) and prenylamine 
(lo-’ M) inhibited the K+ release induced by PTX. 
Compound 48/80 (500 pg/ml) also significantly in- 
hibited the PTX-induced K+ release. Trifluoper- 
azine (10e4 M) and R-24571 (calmidazolium) 
(low6 M), caused hemolysis by themselves. Vera- 
pamil, a Ca2+ channel antagonist with no affinity 
to calmodulin, did not affect the K+ release due to 
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Fig.3. Inhibitory effects of various calmodulin inhibitors 
on PTX-induced K+ release. The amount of K+ released 
during a 30 min PTX-incubation period was measured 
by flame photometry. Erythrocytes were preincubated 
with calmodulin inhibitors for 10 min and PTX (2 x 
lo-” M) was then added to induced K+ release. (0) 
W-5; (=) W-7; (A) chlorpromazine; (A) prenylamine. 
Abscissa, concentration of drugs (M). Ordinate, amount 
of K+ released by PTX (r70). 
PTX even at a concentration of 10m4 M. 
These results support the hypothesis that PTX 
increases membrane permeability to K+ through 
process(es) mediated by Ca2+ and calmodulin. It 
has recently been suggested that PTX increases the 
ion permeability by binding to (Na+ +K+)- 
ATPase, since ouabain and other cardiac 
glycosides specifically inhibit the action of PTX in 
erythrocytes [lo, 1 l] and smooth muscle cells [12]. 
At present, the interrelationship between the PTX- 
binding to (Na+ +K+)-ATPase and the activation 
of calmodulin-mediated process(es) remains to be 
elucidated. 
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